---
title: "Huahao Zhongtian Pharmaceutical has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275254476.md"
description: "Huahao Zhongtian Pharmaceutical announced that the company has received a filing notice from the China Securities Regulatory Commission regarding its application issued on February 5, 2026. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares. The filing notice will be valid for 12 months from the date of issuance and will apply to the Stock Exchange for conversion and listing. However, the details of the conversion and listing implementation plan have not yet been finalized"
datetime: "2026-02-09T02:14:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275254476.md)
  - [en](https://longbridge.com/en/news/275254476.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275254476.md)
---

# Huahao Zhongtian Pharmaceutical has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares

Huahao Zhongtian Pharmaceutical (02563.HK) announced that the company has received a filing notice from the China Securities Regulatory Commission regarding its application issued on February 5, 2026. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares. The filing notice will be valid for 12 months from the date of issuance and will apply to the Stock Exchange for conversion and listing. However, the details of the conversion and listing implementation plan have not yet been finalized

### Related Stocks

- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [02563.HK](https://longbridge.com/en/quote/02563.HK.md)

## Related News & Research

- [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md)
- [CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial](https://longbridge.com/en/news/288238438.md)
- [Beijing Biostar Pharmaceuticals Plans Discretionary H-Share Buy-Back to Signal Confidence](https://longbridge.com/en/news/285579919.md)
- [Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial](https://longbridge.com/en/news/288172168.md)
- [Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape](https://longbridge.com/en/news/285930281.md)